69 results about "Tachycardia" patented technology

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

Described herein are apparatuses and methods to detect tachycardias and selectively reject false tachycardia detections due to T-wave oversensing or noise. An apparatus includes electrodes, a sensing circuit coupled to at least two of the electrodes and configured to sense a signal indicative of cardiac electrical activity, and a smoothing filter configured to filter to the sensed signal indicative of cardiac electrical activity to thereby produce a filtered signal indicative of cardiac electrical activity. The apparatus produces a difference signal indicative of cardiac electrical activity by determining a difference between the sensed and filtered signals indicative of cardiac electrical activity. The apparatus also includes at least one processor configured to detect a tachycardia, or to determine whether or not to reject a tachycardia detection, based on the difference signal. The smoothing filter and / or difference circuitry can be implemented by the at least one processor, and / or other circuitry.

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

A method includes applying pacing to ventricle of heart of patient from multiple electrode locations over circumference of multi-electrode catheter area. Cardiac signals are received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations among the received signals. Based on calculated correlations, the area is checked if it includes an arrhythmogenic location identified with predefined sufficient spatial resolution. If the resolution is insufficient, sub-area to pace is defined. Subsequent pacing is applied to ventricle from multiple electrode locations over a circumference of the sub-area. Subsequent cardiac signals are received in response to the subsequent pacing. Subsequent correlations among the subsequent received signals are calculated. Based on the subsequent correlations, it is ascertained whether the arrhythmogenic location is found in the sub-area. If an arrhythmogenic location is found with sufficient spatial resolution, the identified arrhythmogenic location is indicated to user.

The invention relates to a construction method and application of a spontaneous and persistent ventricular tachycardia animal model, in particular to a spontaneous and persistent ventricular tachycardia rat model based on MYL4 gene defect and myocardial infarction induction. The model is constructed by utilizing the synergistic effect of double pathological factors of MYL4 gene conserved gene defects and acquired myocardial infarction, the induction rate of the model is greater than or equal to 90%, the spontaneous duration time reaches 1-3 min, and the method is obviously superior to an existing construction method for inducing the spontaneous and continuous ventricular tachycardia model. The model can simulate the pathophysiological process of ventricular tachycardia after human MYL4 gene related cardiovascular diseases combined with myocardial infarction, provides general technical support for ventricular arrhythmia pathogenesis research, drug screening and medical instrument research and development, and has wide scientific research and clinical transformation value.

A catheter utilizes a distal electrode array configured for quantification of endocardial or epicardial propagation velocity, with electrodes defining approximately equilateral triangles, such that the calculated velocity can be approximated regardless of the wave front direction. The distal electrode array can also include resilient splines carrying the electrodes such that the splines can deform to ensure contact between the electrodes and the heart tissue. Additionally, the electrodes of the distal electrode array can be individually addressable. Bipolar ablation lines or boxes can also be implemented using two parallel catheters at the endocardium and at the epicardium. Certain configurations include one or more distal electrode arrays of sufficient size to span an entire ventricular tachycardia (VT) circuit. The catheter may also be configured to detect block lines by pacing from edge pacing electrodes of the distal electrode array, and / or to detect fiber orientation by pacing from several edge pacing electrodes.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The utility model discloses a rehabilitation auxiliary blowing assembly which comprises a blowing pipe and further comprises a blowing assembly body arranged on the blowing pipe and used for supraventricular tachycardia treatment, the blowing assembly body comprises a blowing opening and a connecting pipe which are installed at the front end and the rear end of the blowing pipe in a communicated mode, and an installation pipe is fixedly arranged on the outer side of the blowing pipe in a communicated mode. A balloon is detachably mounted on the mounting pipe through a limiting assembly. According to the rehabilitation assisting air blowing assembly, in the process of supraventricular tachycardia treatment and rehabilitation through the air blowing assembly, chest pressure is increased through the air blowing process, blood circulation and autonomic nerve function states are affected, the effect of supraventricular tachycardia treatment and rehabilitation is further achieved, and in the whole treatment process, the recovery effect is improved, and the recovery rate of supraventricular tachycardia is increased. The treatment effect is ensured, and meanwhile, the treatment effect can be visually judged conveniently through deformation of the balloon and display of the pressure gauge.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

This disclosure is directed to systems and techniques for determining an evidence level of an atrial tachycardia (AT) episode based on heart beat intervals in the cardiac activity data over a pre-determined time period. Based on a determination that the evidence level indicates relatively regular heart beat intervals, the example techniques apply a first set of AT detection criteria and indicate a detection of an AT episode based on satisfaction of at least one of the first set of AT detection criteria. Based on a determination that the evidence level indicates relatively irregular heart beat intervals, the example techniques apply a second set of AT detection criteria and indicate a detection of an AT episode based on based on satisfaction of at least one of the second set of AT detection criteria.

The invention discloses a sweat and heart rate detection integrated multi-mode flexible sensor, a preparation method and a detection system. The sweat and heart rate detection integrated multi-mode flexible sensor comprises a multi-mode flexible sensor patch and a collector, the multi-mode flexible sensor patch comprises a release film layer, a skin glue layer, an electrode layer, a flow channel layer and a film covering layer which have the same main body shape and are arranged in sequence, and the collector is fixed on the upper surface of the multi-mode flexible sensor patch and is electrically connected with the multi-mode flexible sensor patch. The multi-mode flexible sensor integrates a sweat detection sensor and a heart rate detection sensor (ECG sensor), sweat and the heart rate can be detected at the same time, electrolyte unbalance in the sweat may be accompanied by heart rate abnormity (such as tachycardia caused by hypokalemia), the diagnosis accuracy can be improved through combined monitoring, and the diagnosis efficiency is improved. More comprehensive physiological information can be provided for the user through physiological indexes (sweat), cardiac functions (ECG) and behavior data (movement and sleep).

The invention concerns the use of compounds represented by formula (I)as inotropic agents. The compounds of formula (I), which include, as preferred, 1-[(1S)-1-(2,3-dichloro-4-methoxyphenyl)ethyl]-3-methyl-3-[(4R)-1-methyl-3,3-dimethyl-4-piperidyl]-urea and its hydrochloride salt, are herein reported to have a significant inotropic activity on cardiomyocytes from both normal and myocardial infarction-induced heart failure animal models, which makes them useful for treating cardiovascular patients in need thereof. Differently from known inotropic agents, the present compounds are effective on cardiomyocyte contractility without influencing calcium mobilization. Accordingly, they are advantageously free from adverse effects caused by increased calcium concentrations, such as increased oxygen demand, tachycardia, arrhythmia, ischemia, etc. Overall, a new, safe and effective inotropic treatment is thus made available.

A system includes a catheter, an electrocardiogram (ECG) system, and a processor. The catheter is configured to apply pacing to a given tissue location inside a ventricle of a heart of a patient. The ECG system is configured to acquire a set of ECG signals generated in response to the pacing, wherein electrodes of the ECG system attached to the patient define respective directions in space with respect to an origin located in the heart. The processor is configured to (i) compute a set of respective signal differences between the acquired set of ECG signals and a reference set of ECG signals, (ii) compute a set of corresponding deviation vectors along the respective directions in the space, the deviation vectors having magnitudes corresponding to the respective signal differences, (iii) using the deviation vectors, compute a direction vector from the given location to a new ventricle location at which to apply the pacing, and (iv) indicate the computed direction vector to a user.

The present invention provides compositions and methods for treating Postural orthostatic tachycardia syndrome (POTS). In some embodiments, the POTS is associated with hypermobility spectrum disorders / hypermobile Ehlers-Danlos syndrome (HSD / hEDS). In various embodiments, the invention relates to administering a composition comprising an effective amount of a molecular antagonist of Glucose-dependent Insulinotropic Polpeptide (GIP) to a patient in need thereof. In various embodiments, the molecular antagonist can be provided in a form for convenient self-administration upon the onset of symptoms or to prevent or reduce postprandial POTS symptoms, or in other embodiments, is administered at a set frequency.

A computer device for processing cardiac signals comprises: - a data storage (114) arranged to receive input data sets each comprising a plurality of P wave segments each associated with an electrocardiogram track and with an acquisition time window, and a plurality of coronary sinus signals associated with the same acquisition time window and having one or more activation sequence, - an input module comprising a plurality of classifiers, each associated with a respective atrial tachycardia class and arranged to receive an input data set, and to return a value indicating the probability that the input data set indicates an atrial tachycardia which belongs to the associated atrial tachycardia class, each classifier being further associated with a respective confusion matrix, said atrial tachycardia classes being arranged into a hierarchy made of layers each comprising one more node, each node of a given layer being connected to at least one other node in the hierarchy, only part in the layer immediately above and / or in the layer immediately below said given layer in said hierarchy, - a Bayesian engine comprising a prevalence matrix for pair of classifiers which atrial tachycardia classes are connected in said atrial tachycardia class hierarchy, arranged to receive a set of assessments comprising an atrial tachycardia class probability for each classifier, and to process said set of assessments according to the confusion matrices associated with the classifiers and according to said prevalence matrices in order to determine an updated set of assessments which maximizes the expression (I), where Z i are the updated set of assessments values, Y i are the set of assessments, YC i represents the states of the child nodes of the classifier associated with Y i in said atrial tachycardia class hierarchy, and N is the total number of classifiers, said device being arranged to receive an input data set, to process it with the input module, to derive therefrom a set of assessments provided to said Bayesian engine, and to return one or more atrial tachycardia information derived from said updated set of assessments.

Substernal implantable cardioveter-defibrillator (ICD) systems and methods for providing substernal electrical stimulation therapy to treat malignant tachyarrhythmia, e.g., ventricular tachycardia (VT) and ventricular fibrillation (VF) are described. In one example, an implantable cardioveter-defibrillator (ICD) system includes an ICD implanted in a patient and an implantable medical electrical lead. The lead includes an elongated lead body having a proximal end and a distal portion, a connector at the proximal end of the lead body configured to couple to the ICD, and one or more electrodes along the distal portion of the elongated lead body. The distal portion of the elongated lead body of the lead is implanted substantially within an anterior mediastinum of the patient and the ICD is configured to deliver electrical stimulation to a heart of the patient using the one or more electrodes.

A method and an electronic device for detecting a heart rhythm are provided. The method comprises: acquiring a first PPG signal in a first preset time length; determining a plurality of heart rate values based on the first PPG signal; determining a difference value of each two adjacent heart rates based on the plurality of heart rate values, the difference value of each two adjacent heart rates being used to generate a heart rate difference value trajectory graph; acquiring parameters of a heart rate difference value trajectory based on the heart rate difference value trajectory graph, the parameters of the heart rate difference value trajectory comprising one or more of the following parameters: an angle, a number, an angle standard deviation, a distance standard deviation; determining a heart rhythm type of the first PPG signal according to the parameters of the heart rate difference value trajectory, the heart rhythm type comprising any one of the following: a premature beat, an atrial fibrillation, a sinus rhythm, a ventricular tachycardia, a bigeminy, a trigeminy; and displaying the heart rhythm type of the first PPG signal, which can improve the accuracy of identifying a premature beat or an atrial fibrillation, reduce the probability of identifying a premature beat as an atrial fibrillation, and improve user experience.

A method and medical device for detecting a cardiac event that includes sensing cardiac signals from a plurality of electrodes, the plurality of electrodes forming a first sensing vector and a second sensing vector, identifying the cardiac event as one of a shockable event and a non-shockable event in response to first processing of a first interval sensed along the first sensing vector during a predetermined sensing window and a second interval simultaneously sensed along the second sensing vector, performing second processing of the first interval and the second interval, different from the first processing, in response to the cardiac event being identified as a shockable event, and determining whether to delay identifying the cardiac event being shockable in response to the second processing of the first interval and the second interval.

The invention relates to identification of ventricular tachycardia (VT) targets by selective pacing. A method includes applying pacing to a ventricle of a heart of a patient from a plurality of electrode locations on a circumference of a multi-electrode catheter region. A cardiac signal is received in response to the pacing. A correlation algorithm is applied to the received signals to calculate a plurality of correlations between the received signals. Based on the calculated correlation, it is checked whether the region includes an arrhythmic location identified at a predefined sufficient spatial resolution. If the resolution is insufficient, the sub-region to be paced is defined. Subsequent pacing is applied to the ventricle from a plurality of electrode locations on the circumference of the sub-region. A subsequent cardiac signal is received in response to the subsequent pacing. A subsequent correlation between the subsequently received signals is calculated. Based on the subsequent correlations, it is determined whether to find the arrhythmic location in the sub-region. If an arrhythmic location is found with sufficient spatial resolution, the identified arrhythmic location is indicated to the user.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

VfA cardiac therapy uses an implantable medical device or system. The implantable medical device includes a tissue-piercing electrode implanted in the basal and / or septal region of the left ventricular myocardium of the patient's heart from the triangle of Koch region of the right atrium through the right atrial endocardium and central fibrous body. The device may include a right atrial electrode, a right atrial motion detector, or both. The device may be implanted completely within the patient's heart or may use one or more leads to implant electrodes in the patient's heart. The device may be used to provide cardiac therapy, including single or multiple chamber pacing, atrioventricular synchronous pacing, asynchronous pacing, triggered pacing, cardiac resynchronization pacing, or tachycardia-related therapy. A separate medical device may be used to provide some functionality for cardiac therapy, such as sensing, pacing, or shock therapy.

Critical isthmus for treatment of tachycardia via application of ablation therapy may be automatically identified by an electroanatomical mapping system from voltage and timing maps of a portion of a patient's heart. The system identifies one or more low-voltage regions from the voltage map and one or more deceleration zones from the timing map. Based on the identified low-voltage regions and deceleration zones, the system can generate an output including an identification of one or more critical isthmus locations through application of a classifier trained with data from a plurality of subjects that received ablation therapy for treatment of tachycardia. The system can also output a tachycardia termination confidence value for each identified critical isthmus location. The classifier may employ a convolutional neural network algorithm.

An implantable medical device implantable in a human or animal heart that carries out the following steps during its operation: a) continuously detecting a cardiac electric signal; b) starting a coagulation timer if the detected cardiac electric signal is indicative for an atrial tachycardia; c) keeping the coagulation timer active during a temporary loss of the cardiac electric signal; and d) stopping the coagulation timer, if the following criteria are fulfilled: i) an amplitude of the cardiac electric signal of a plurality of cardiac intervals being close in time exceeds a presettable significance threshold, and ii) an atrial rate calculated from the plurality of cardiac intervals being close in time is below a predefinable threshold rate indicative for atrial tachycardia, or e) keeping the coagulation timer active for a predefined time period, if the criteria are not fulfilled.

The application discloses a traditional Chinese medicine preparation for treating tachycardia, which is prepared from the following raw medicinal materials: cassia twig 10-20 g, white atractylodes 10-20 g, radix codonopsis 15-25 g, prepared rehmannia 15-25 g, raw oyster shell 25-35 g, raw concha mallei 25-35 g, sophora flavescens 10-20 g, schisandra chinensis 10-20 g, gancao 15-25 g, ophiopogon japonicus 10-20 g, and turtle shell 10-20 g. The traditional Chinese medicine preparation for treating tachycardia is orally taken in a daily dose, and is taken twice a day, in the morning and in the evening, half an hour after meals, and is continuously taken for 4 weeks as a treatment course. The traditional Chinese medicine preparation for treating tachycardia can obviously improve symptoms such as palpitation, short breath, five heart heat, hot flashes, insomnia, dreaminess, anxiety and the like, has a remarkable curative effect, is safe, is cheap and simple, and has a high clinical promotion value.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.